Related Experiment Videos
Pharmaceutical development of ondansetron injection
1Glaxo Group Research Ltd., Ware, Hertfordshire, U.K.
European Journal of Cancer & Clinical Oncology
|January 1, 1989
Summary
Ondansetron injection, an antiemetic, is stable for 3 years and compatible with various IV fluids and chemotherapy drugs. This formulation ensures reliable administration for patients undergoing treatment.
Area of Science:
- Pharmaceutical Science
- Oncology Pharmacy
Background:
- Ondansetron is a serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting.
- Optimizing the formulation and administration of ondansetron injection is crucial for patient care, especially in oncology.
Purpose of the Study:
- To characterize the stability and compatibility of ondansetron hydrochloride dihydrate injection.
- To provide guidance on the safe and effective administration of ondansetron injection in clinical settings.
Main Methods:
- Chemical and physical stability assessments of ondansetron injection.
- Compatibility studies with common intravenous infusion fluids and select chemotherapeutic agents.
Main Results:
- Ondansetron injection exhibits good physical and chemical stability when stored below 30°C and protected from light, with a shelf life of 3 years.
- The injection is compatible with various intravenous fluids and can be co-administered with specific concentrations of several chemotherapy drugs, including cisplatin and doxorubicin.
Conclusions:
- Ondansetron injection is a stable pharmaceutical preparation suitable for long-term storage.
- The demonstrated compatibility supports the co-administration of ondansetron with common IV fluids and essential chemotherapy agents, facilitating flexible patient treatment regimens.